Monitoring and evaluating the quality of XXXX care in Japan using administrative claims data.

@entity5 @entity1 @entity0
UNASSIGNED: The importance of measuring the quality of @entity5 care has been well recognized in many developed countries, but has never been successfully implemented on a national level in Japan. We sought to establish a wide-scale quality monitoring and evaluation program for @entity5 by measuring 13 process-of-care quality indicators (QIs) using registry-linked claims database. We measured two QIs on pre-treatment testing, nine on adherence to clinical guidelines on therapeutic treatments, and two on supportive care, for breast, prostate, colorectal, stomach, lung, liver, and cervical @entity5 @entity1 who were diagnosed in 2011 from 178 hospitals. We further assessed the reasons for non-adherence for @entity1 who did not receive the indicated care in 26 hospitals. QIs for pretreatment testing were high in most hospitals (above 80%), but scores on adjuvant radiation and chemoradiation therapies were low (20-37%) except for @entity0 (74%). QIs for adjuvant chemotherapy and supportive care were more widely distributed across hospitals (45-68%). Further analysis in 26 hospitals showed that most of the @entity1 who did not receive adjuvant chemotherapy had clinically valid reasons for not receiving the specified care (above 70%), but the majority of the @entity1 did not have sufficient reasons for not receiving adjuvant radiotherapy (52-69%) and supportive care (above 80%). We presented the first wide-scale quality measurement initiative of @entity5 @entity1 in Japan. @entity1 without clinically valid reasons for non-adherence should be examined further in the future to improve care. This article is protected by copyright. All rights reserved.
